Exploring Latin America In The COVID-19 Era

 
• By Ben Comer
  
Generate a summary of this article
Listen to this article
Beta

Unique industry partnerships and new regulatory flexibility in Latin America may help to improve access to medicines, even as COVID-19 wreaks havoc in the region’s largest pharmaceutical market. Can biopharma’s bespoke solutions to market access barriers coalesce into a strategy capable of overcoming political, economic and COVID-19 related risks?   

IV2006_Latin-America_COVID19_feature-image_1200.jpg

At the BIO 2020 conference in June, which was held virtually due to the COVID-19 pandemic, speakers on a panel about the impact of coronavirus on health care delivery worried aloud about a coming reduction of public funds for medicines in the US and Europe. An economic recession, speakers feared, could lead to reductions in drug coverage and cost containment measures in the world’s largest markets. To prevent a tightening in market access, the biopharma industry will have to “find innovative solutions ourselves and collaborate with health systems and policy makers to enact them,” said Stefan Neudoerfer, senior director, head of market access Europe, CSL Behring.

This strategy – of creating solutions in collaboration with key stakeholders in individual markets – is already playing out in...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Market Access

How To Decarbonize Pharma R&D

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.

IV-MarketAccess (Premium-1): Stimulant Medications Don’t Cause Psychosis, New Study Finds

 
• By Nabil

Instead, the new study found children with more severe attention and hyperactivity issues or other mental health conditions such as anxiety were more likely to be medicated for ADHD.

[Test]With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By Nabil

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

In Search Of Rare Disease Treatments, Nonprofits Can Lead the Charge

 
• By David Wild

Nonprofits are finding new ways to address market gaps and develop treatments for rare diseases with little commercial attraction.

More from In Vivo

In Vivo’s 2026 Rising Leaders-Part 1

 
• By Saba Afreen

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

XXXXtesting

 
• By Saba Afreen

XXXXtesting

In Vivo’s 2026 Rising Leaders At A Glance

 
• By Saba Afreen

Top 30 leaders: see the list of industry influencers highlighted in the sixth edition of In Vivo's Rising Leaders series.